Metraipolis › archive › dc_6400a421c9da

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases — Europe PMC PMID:41992832

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41992832
DOI: 10.1093/oncolo/oyag146
License (as archived): solo-consultazione
Archived: 2026-11-03T13:26:41.966Z
SHA-256 of the archived text: 53f94cd69bf5bf965229ac05dcce82bf565c31a09916a48a10cd6b88cfc0a433
Stable URL of this page: https://metraipolis.com/documento/dc_6400a421c9da

How to cite

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases — Europe PMC PMID:41992832 — Europe PMC (en), https://europepmc.org/article/MED/41992832 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6400a421c9da (Metraipolis archive dc_6400a421c9da, sha256 53f94cd69bf5bf965229ac05dcce82bf565c31a09916a48a10cd6b88cfc0a433)

BibTeX

@misc{dc6400a421c9da,
  title = {Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases — Europe PMC PMID:41992832},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41992832},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6400a421c9da; sha256 53f94cd69bf5bf965229ac05dcce82bf565c31a09916a48a10cd6b88cfc0a433},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41992832. Agents can read the archived copy with the MCP tool read_document.